Premium
Intraumbilical injection of uterotonics for retained placenta
Author(s) -
Habek D.,
Franičević D.
Publication year - 2007
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2007.05.007
Subject(s) - medicine , uterotonic , oxytocin , saline , umbilical vein , pregnancy , uterine atony , placenta , obstetrics , retained placenta , prostaglandin , uterus , anesthesia , fetus , surgery , hysterectomy , biochemistry , chemistry , biology , in vitro , genetics
Objective To assess the effect of injecting an uterotonic agent in the umbilical vein during the third stage of labor in women with retained placentas. Methods In this prospective clinical study, 75 women with retained placentas received 20 mL of a 0.9% saline solution with either 20 IU of oxytocin ( n = 54), 0.5 mg of carboprost tromethamine ( n = 7), or 0.2 mg of methylergometrine ( n = 14) injected in the umbilical vein after clamping. The treatment success was determined by the clinical signs of placental ablation. Results There were no statistically significant differences among the 3 therapeutic groups regarding age, parity, risk factors, pregnancy duration, type of delivery (spontaneous, induced, or augmented), or possible early postpartum complications caused by the intraumbilical injection. The rates of therapeutic success were 76.9% in the oxytocin group, 85.7% in the synthetic prostaglandin group, and 64.2% in the methylergometrine group. Conclusion The intraumbilical injection of uterotonics is a noninvasive, effective, and clinically safe method of shortening the third stage of labor in women with retained placentas.